JP2020522506A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522506A5
JP2020522506A5 JP2019566594A JP2019566594A JP2020522506A5 JP 2020522506 A5 JP2020522506 A5 JP 2020522506A5 JP 2019566594 A JP2019566594 A JP 2019566594A JP 2019566594 A JP2019566594 A JP 2019566594A JP 2020522506 A5 JP2020522506 A5 JP 2020522506A5
Authority
JP
Japan
Prior art keywords
group
psma
tumors
compound
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566594A
Other languages
English (en)
Japanese (ja)
Other versions
JP7821460B2 (ja
JP2020522506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/035220 external-priority patent/WO2018222778A1/en
Publication of JP2020522506A publication Critical patent/JP2020522506A/ja
Publication of JP2020522506A5 publication Critical patent/JP2020522506A5/ja
Priority to JP2023127925A priority Critical patent/JP2023159182A/ja
Priority to JP2024221155A priority patent/JP2025041719A/ja
Application granted granted Critical
Publication of JP7821460B2 publication Critical patent/JP7821460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566594A 2017-05-30 2018-05-30 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 Active JP7821460B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023127925A JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512515P 2017-05-30 2017-05-30
US62/512,515 2017-05-30
PCT/US2018/035220 WO2018222778A1 (en) 2017-05-30 2018-05-30 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023127925A Division JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Publications (3)

Publication Number Publication Date
JP2020522506A JP2020522506A (ja) 2020-07-30
JP2020522506A5 true JP2020522506A5 (https=) 2021-01-07
JP7821460B2 JP7821460B2 (ja) 2026-02-27

Family

ID=64455570

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019566594A Active JP7821460B2 (ja) 2017-05-30 2018-05-30 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2023127925A Pending JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A Pending JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023127925A Pending JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A Pending JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Country Status (5)

Country Link
US (2) US11478558B2 (https=)
EP (1) EP3630733A4 (https=)
JP (3) JP7821460B2 (https=)
CN (2) CN111032632B (https=)
WO (1) WO2018222778A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813340B2 (en) 2018-02-06 2023-11-14 The Johns Hopkins University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
CN114364405B (zh) * 2019-04-26 2024-07-16 五一一制药股份有限公司 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂
CN114096526A (zh) * 2019-07-02 2022-02-25 诺华股份有限公司 前列腺特异性膜抗原（psma）配体及其用途
PH12021553284A1 (en) * 2019-07-02 2022-08-01 Advanced Accelerator Applications Italy Srl Prostate specific membrane antigen (psma) ligands and uses thereof
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
JP2023522983A (ja) * 2020-04-24 2023-06-01 ラジオメディックス インコーポレイテッド 前立腺がんの診断および処置のための組成物、キットおよび方法
AU2021267477A1 (en) * 2020-05-06 2022-12-01 Cornell University Copper-containing theragnostic compounds and methods of use
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
WO2022043556A1 (en) * 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4204020A1 (en) * 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) * 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
AU2021390552A1 (en) * 2020-12-04 2023-06-29 The Regents Of The University Of California Peptide receptor radionuclide therapy
CN113077840B (zh) * 2021-04-21 2023-01-31 四川大学 基于药效团与alpha-碳特征的金属酶活性位点对比方法
EP4475900A1 (en) * 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
WO2024243315A2 (en) * 2023-05-22 2024-11-28 Actinium Pharmaceuticals, Inc. Multi-arm bifunctional chelators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700234T3 (es) * 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
JP2012511024A (ja) * 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 癌の治療及び撮像用のｃａ−ｉｘ特異性放射性医薬品
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
AU2012294639B2 (en) * 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
ES2729555T3 (es) * 2011-11-30 2019-11-04 Univ Johns Hopkins Inhibidores homomultivalentes y heteromultivalentes de antígeno de membrana específico de próstata (PMSA) y usos de los mismos
EP3939972A1 (en) 2013-01-14 2022-01-19 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
EP3456700A1 (en) * 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN106660943B (zh) * 2014-05-06 2020-03-17 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
JP2017530109A (ja) * 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護
EP3212610B1 (en) * 2014-10-30 2020-10-28 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
RS65188B1 (sr) 2016-03-22 2024-03-29 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate

Similar Documents

Publication Publication Date Title
JP7821460B2 (ja) 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2020522506A5 (https=)
JP7630149B2 (ja) Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤
JP7073270B2 (ja) 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
CN110612126B (zh) 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
EP3609544B1 (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
KR20230165818A (ko) 섬유아세포 활성화 단백질 알파 및/또는 전립선-특이적 막 항원을 표적화하는 이종이가 및 동형이가 제제
US20210040126A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
WO2016065145A2 (en) Psma targeted reversed carbamates and methods of use thereof
US20210121584A1 (en) Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
US11078166B2 (en) Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
WO2016149188A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
CN115745903B (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
WO2025042989A1 (en) Psma-based albumin binding agents for targeted radionuclide therapy of prostate cancer